Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Drug Safety Oversight Board Should Have More Independent Outside Advisors, Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Board Executive Director Susan Cummins maintains that as a "management tool," the DSOB must run in a different way from a public advisory committee.

You may also be interested in...



FDA Should Consider Ethicist For Drug Safety Oversight Board, Science Board Chair Says

An ethicist could provide input on risk/benefit issues on behalf of the public, UT’s Shine suggests.

FDA Should Consider Ethicist For Drug Safety Oversight Board, Science Board Chair Says

An ethicist could provide input on risk/benefit issues on behalf of the public, UT’s Shine suggests.

FDA Drug Safety Board To Meet Every Six Weeks

The board discussed FDA's recent action on fentanyl transdermal patches (J&J's Duragesic and generics) and Purdue's Palladone (hydromorphone extended-release) during a July 27 meeting, FDA's meeting summary says.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel